Industry

Ocugen Completes Dosing Ahead of Schedule in Pivotal Stargardt Disease Gene Therapy Trial

Eyewire+1d ago2 min read

Key Takeaways Ocugen completed dosing ahead of schedule in its phase 2/3 GARDian3 trial for OCU410ST, a one-time gene therapy candidate for Stargardt disease The study enrolled 63 patients across a broad age and disease spectrum, with early data expected in Q3 2026 and a planned BLA submission in mid-2027 OCU410ST has shown a favorable safety profile so far and aims to slow retinal degeneration and preserve vision in patients with ABCA4-associated retinopathies Ocugen announced that it has successfully completed dosing ahead of schedule in its phase 2/3 GARDian3 pivotal clinical trial for OCU410ST (AAV5-hRORA), a modifier gene therapy candidate targeting Stargardt disease. “This enrollment milestone for a pivotal trial underscores the tremendous progress our team is making toward bringing a transformative therapy to people living with multiple ABCA4-related gene mutations including Stargardt disease,” said Shankar Musunuri, PhD, Chairman, CEO, and Co-founder of Ocugen. “The efficient and accelerated execution of this trial reflects strong engagement from investigators and patients, reinforcing our confidence in OCU410ST as a potential one-time treatment option.” The GARDian3 trial is a multicenter, randomized, masked phase 2/3 study evaluating the safety and efficacy of OCU410ST across a broad population of Stargardt patients. The study enrolled 63 participants spanning pediatric to adult populations and ranging from early to advanced stages of the disease. Participants in the treatment arm received a single subretinal injection of OCU410ST in the eye with poorer visual acuity, while the control group received no treatment. The therapy utilizes Ocugen’s AAV5-based platform to deliver the hRORA gene, aiming to slow or halt retinal degeneration and preserve vision. The trial’s primary endpoint is the reduction in atrophic lesion size at 12 months. Secondary endpoints include improvements in best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA). Researchers will also assess preservation of the Ellipsoid Zone (EZ), a key retinal structure associated with visual function. Ocugen plans to conduct an interim analysis in the third quarter of 2026 after 24 patients complete an 8-month follow-up. Data from the 1-year follow-up are expected to support a planned Biologics License Application (BLA), which the company aims to submit by mid-2027. To date, OCU410ST has demonstrated a favorable safety and tolerability profile, with no serious adverse events or notable complications reported. The GARDian3 study represents Ocugen’s second late-stage clinical program and aligns with the company’s broader strategy to submit three BLAs by 2028.

Read full article on Eyewire+

AI Summary

Quick Take

Ocugen has completed dosing ahead of schedule in its pivotal Phase 2/3 GARDian3 trial for OCU410ST, a one-time gene therapy candidate for Stargardt disease. The study enrolled 63 patients across a broad age and disease spectrum to evaluate the therapy's ability to slow retinal degeneration by delivering the hRORA gene via a subretinal injection.

Why It Matters

Stargardt disease is the most common inherited macular dystrophy, yet it currently lacks FDA-approved treatments to halt its progression. This trial is significant because OCU410ST utilizes a modifier gene therapy approach, which may address a broader range of ABCA4-related retinopathies compared to traditional gene replacement. The accelerated enrollment reflects a high level of clinical interest and patient demand for a solution to a condition that typically leads to early and irreversible central vision loss.

Key Findings

The trial successfully enrolled 63 participants, including both pediatric and adult populations with disease stages ranging from early to advanced.
OCU410ST has demonstrated a favorable safety and tolerability profile so far, with no serious adverse events reported.
The primary efficacy endpoint is the reduction in atrophic lesion size at 12 months post-treatment.
Secondary measures include improvements in best corrected visual acuity (BCVA), low luminance visual acuity (LLVA), and the preservation of the Ellipsoid Zone (EZ).

Study Snapshot

Design

Multicenter, randomized, masked Phase 2/3 pivotal clinical trial

Population

Pediatric and adult patients with Stargardt disease (ABCA4 mutations)

Sample Size

63 participants

Practice Implications

Retina specialists and pediatric ophthalmologists should note OCU410ST as a leading candidate for Stargardt disease management. If the 12-month data confirms a reduction in atrophic lesion growth, this therapy could transition the clinical approach from supportive low-vision care to a proactive, one-time intervention aimed at preserving functional retinal structures like the Ellipsoid Zone.

Who's Affected

Retina SpecialistsPediatric OphthalmologistsGenetic CounselorsLow Vision Specialists

What's Next

An interim analysis of 24 patients who have reached the 8-month follow-up mark is expected in the third quarter of 2026. Ocugen plans to use the full one-year data to support a Biologics License Application (BLA) submission targeted for mid-2027.

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.